Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

SQI Diagnostics to Announce Second Quarter 2017 Results

V.SQD.H

Canada NewsWire

TORONTO, May 3, 2017 /CNW/ - SQI Diagnostics Inc. ("SQI Diagnostics" or the "Company") (TSX-V: SQD; OTCQX: SQIDF), today announced that it plans to release its financial and operational results for the three and six months ended March 31, 2017 at 4:30 p.m. ET Wednesday, May 10, 2017.  President and CEO, Andrew Morris, along with Company management, will host a conference call on Wednesday, May 10, 2017 at 5:00 p.m. ET to review financial results and discuss business developments for the period. 

Conference Call Details:

Date:

Wednesday May 10, 2017

Time:

5:00 p.m. ET

Live Call:

1-888-231-8191 (Canada and the United States)

Conference ID:

15154556

Webcast:

http://event.on24.com/r.htm?e=1417487&s=1&k=EBAB4C8B4D3C0B7FB0D4263C284F7F54

 

 

An archived copy of the conference call will be available for 90 days on the Company website at www.sqidiagnostics.com/about/investors  and also at http://event.on24.com/r.htm?e=1417487&s=1&k=EBAB4C8B4D3C0B7FB0D4263C284F7F54.

Detailed financial statements and the management's discussion and analysis (MD&A) will also be made available on the Company website at www.sqidiagnostics.com and at www.sedar.com.

About SQI Diagnostics

SQI Diagnostics is a life sciences and diagnostics company that develops clinical grade multiplexed microarray and molecular assays run on its automated instrumentation for the pharmaceutical research, animal health, and clinical diagnostics markets. SQI develops custom research and diagnostic assays that are multiplexed; meaning the simplification, consolidation and automation of many individual tests into one. This increases sample throughput, reduces time, cost and chance for human error, and provides excellent data quality. For more information, please visit sqidiagnostics.com.

Forward-looking Statements

This press release contains certain words and statements, which may constitute "forward-looking statements" within the meaning of applicable securities laws.  Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties detailed in the Company's ongoing filings with the securities regulatory authorities, available to the public at www.sedar.com .  Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE SQI Diagnostics Inc.

View original content: http://www.newswire.ca/en/releases/archive/May2017/03/c4573.html



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today